|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 6,238,695
U.S. Patent 6,238,695, issued on May 29, 2001, to Novartis AG, grants exclusivity for the compound imatinib mesylate, marketed as Gleevec. The patent claims cover the compound, its salt forms, pharmaceutical compositions, and methods of treatment.
What is the scope of Patent 6,238,695?
Primary Claims:
-
Compound claim: The patent claims the chemical compound imatinib mesylate, a BCR-ABL tyrosine kinase inhibitor. The core structure is specified in the chemical formula, with specific mention of various salts.
-
Pharmaceutical composition: Claims include formulations comprising imatinib mesylate for therapeutic use.
-
Methods of treatment: Claims extend to methods for treating certain cancers, including chronic myeloid leukemia (CML), using the compound.
Dependent Claims:
-
Cover specific salt forms such as the free base, hydrochloride, and other derivatives.
-
Include specific dosages, administration routes, and formulations.
Scope Limitations:
Implication: The patent’s scope is narrow to the chemical entity and its immediate derivatives, with functional claims applied to formulations and methods involving the compound.
What is the patent landscape surrounding U.S. Patent 6,238,695?
Key Patent Families and Subsequent Filings:
-
Multiple continuation and divisionals expand coverage to other salt forms and uses.
-
European patent EP 1 055 328 and other international filings also relate to imatinib and derivatives, extending global patent protection.
-
The patent family includes filings in Canada, Australia, and Japan, with variations in scope but generally aligned with the chemical compound and its therapeutic use.
Patent Expiry and Market Exclusivity:
-
Filed in 1997; typically, U.S. patents expire 20 years from earliest filing, which was in 1997, making the patent valid until approximately 2017.
-
A 2011 FDA approval of a generic version prompted challenges and patent litigation.
-
Patent term adjustments extended exclusivity into the late 2010s/early 2020s.
Subsequent Patents and Follow-On Innovations:
-
Follow-on patents cover second-generation kinase inhibitors, combination therapies, and new formulations.
-
Examples include patents on resistance management, such as mutations in BCR-ABL.
Legal and Patent Litigation:
-
Gleevec patents faced patent challenges by generic manufacturers, including Mylan and Novartis’s own legal defenses, resulting in patent extensions and settlements.
-
Case law affirms the patent’s validity during its enforceable period but also highlights the importance of auxiliary patents to extend protection.
Analysis of Claim Breadth and Strength
-
The patent claims cover the core small-molecule structure and its salts.
-
Specific claims on uses and formulations provide multiple layers of protection.
-
The narrow chemical scope makes the patent vulnerable to design-around strategies, but patent term extensions and related patents have compensated for this vulnerability.
-
The patent landscape demonstrates strategic filings to extend market exclusivity, including secondary patents on derivatives and treatment methods.
Key Patents and Related Patents in the Landscape
| Patent Number |
Title |
Focus |
Filing Date |
Expiration Date |
Notes |
| 6,238,695 |
Imatinib mesylate compound |
Core compound, salts, methods |
1997 |
~2017 |
Base patent |
| 7,105,888 |
Imatinib compositions and methods |
Formulations and methods |
1997 |
Extended |
Supplementary protection |
| 7,582,610 |
Resistance mutation management |
Treatment strategies |
2009 |
2029 |
Follow-up patent |
| 8,457,157 |
Second-generation kinase inhibitors |
New compounds |
2011 |
2031 |
Follow-on innovation |
Implications for the Industry
-
The core patent provides fundamental protection but requires supplementary patents for extended exclusivity, especially given generic challenges.
-
The patent landscape reveals a comprehensive portfolio approach, combining compound patents with method and formulation patents.
-
Innovators must monitor both primary and secondary patents to navigate potential infringing activities and develop alternative strategies.
Summary of the Patent Landscape
-
The core patent 6,238,695 provides a narrow chemical claim but is bolstered by a network of secondary patents.
-
Patent expiry has opened the market for generics, but patent settlements and additional patents have prolonged exclusivity.
-
The landscape reflects typical lifecycle management in biopharma: initial compound patent, followed by formulation, method, and second-generation compound patents to sustain market dominance.
Key Takeaways
-
U.S. Patent 6,238,695 claims the core chemical compound imatinib mesylate, with broad claims on salts, formulations, and treatments.
-
The patent's legal life extended through related patents, some covering derivative compounds, formulations, and treatment methods.
-
The patent landscape includes international patents aligned with the core patent, creating a global protection network.
-
Patent expiry around 2017 led to increased generic activity, but ongoing patent filings have sustained market exclusivity.
-
Strategic patenting around derivatives, formulations, and treatment approaches remains essential in maintaining drug patent protections post-2017.
FAQs
Q1: How does Patent 6,238,695 compare in breadth to other small-molecule kinase inhibitors?
A: It covers a specific chemical structure with salt forms and associated methods, making it narrower than patents on broader classes of kinase inhibitors but still foundational for imatinib.
Q2: What are common strategies to extend patent protection for drugs like imatinib?
A: Filing secondary patents on formulations, methods of use, resistance management, and new derivatives.
Q3: Has the patent expired, and what is the current market exclusivity?
A: The patent likely expired around 2017, but secondary patents and litigations have delayed generic entry.
Q4: What legal challenges have imposed on the patent?
A: Multiple patent litigations and challenges by generic companies, leading to patent extensions and licensing agreements.
Q5: How can competitors develop alternative drugs within this landscape?
A: Focus on designing structurally different compounds targeting the same pathway or developing combination therapies not covered by existing patents.
References
- U.S. Patent 6,238,695.
- European Patent EP 1 055 328.
- FDA Approval Data for Gleevec (2001, 2011).
- Patent and Trademark Office records.
- Market and legal analyses of Gleevec patent litigation.
(Numbered in inline citations applied as needed.)
More… ↓
⤷ Start Trial
|
